BACKGROUND Endocrine therapy for prostate cancer aims to reduce the levels of
circulating androgen or to inhibit androgen action by blocking the androgen receptor in the …

Background and objective It has been reported that patients with de novo metastatic
castration-sensitive prostate cancer (dn-mCSPC) have worse prognosis and outcomes than …

BACKGROUND Alterations in the function of androgen receptor (AR) and its signaling
pathway may be responsible for the progression of prostate cancer. The goal of the present …

Emergence of androgen-independent cancer cells during androgen deprivation therapy
presents a significant challenge to successful treatment outcomes in prostate cancer …

BACKGROUND The incidence of, and mortality from, prostate cancer (PCa) has increased
in Asian countries over the past decades, partly due to a change in dietary habits. Recent …

Because of the heterogeneous nature of prostate cancer, identifying the molecular
mechanisms involved during the transition from an androgen-sensitive to an androgen …

Background: Expression of the androgen receptor (AR) is associated with androgen-
dependent proliferation arrest and terminal differentiation of normal prostate epithelial cells …

Androgen ablation is the primary treatment modality for patients with metastatic prostate
cancer; however, the role of androgen receptor signaling in prostate cancer development …

Enhanced intratumoral androgen biosynthesis and persistent androgen receptor (AR)
signaling are key factors responsible for the relapse growth of castration-resistant prostate …

The normal development and maintenance of the prostate is dependent on androgen acting
through the androgen receptor (AR). AR remains important in the development and …